Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect of Mounjaro, affecting a significant proportion of participants in clinical trials — and for many people it peaks in the first few weeks, then fades. Sickness from Mounjaro is real, but it is also manageable, and understanding why it happens is the first step toward getting through it. These are prescription-only medicines; a GPhC-registered prescriber assesses your suitability before treatment begins, and the same clinical team is there if side effects become a concern.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity over 72 weeks and produced the clearest picture we have of how sickness unfolds on tirzepatide. Nausea was reported more often at 5mg, 10mg and 15mg than at the 2.5mg starting dose, which is precisely why the licensed titration schedule begins low and climbs gradually, your system gets a period of adjustment before the dose increases. For most participants, gastrointestinal symptoms were mild to moderate and did not lead to stopping treatment. That context matters. The fact that nausea showed up in trial data does not mean it will be constant, severe, or permanent for you. It tends to spike around dose changes and then settle, often within one to two weeks. If you want practical strategies for those difficult early days, our guide to Mounjaro nausea relief walks through what actually helps when symptoms are at their worst. The NHS tirzepatide page lists nausea alongside vomiting, diarrhoea, constipation and indigestion as the effects most commonly reported, all sharing the same underlying cause.
Tirzepatide activates both GIP and GLP-1 receptors, the only licensed weight-loss medicine in the UK to work on both pathways simultaneously. One consequence of that dual action is a significant slowing of gastric emptying, food moves through your stomach more slowly, you feel fuller sooner, and you eat less. That is the mechanism driving weight loss. It is also the mechanism behind the nausea. When your stomach holds food for longer than it used to, the signals it sends to your brain can read as queasiness, particularly after eating a large meal, a fatty meal, or eating quickly. Understanding this makes the dietary advice below feel less arbitrary. You can read more about why Mounjaro causes sickness and how that changes over time. A separate but related question for some people is headaches, if you are also dealing with those, our page on Mounjaro headache relief covers the evidence there too. The mechanism-first framing also explains why sickness tends to ease between injections and worsen briefly after each new dose: the gut is resetting again.
There is no single answer that works for everyone, but there is a consistent body of prescriber guidance and patient experience pointing in the same direction. Smaller portions eaten slowly, spaced across the day, reduce the load on a stomach that is already emptying more slowly than usual. Low-fat, low-spice meals tend to sit better in the early weeks. Avoiding lying down immediately after eating gives the stomach time to work. Staying well hydrated matters too, nausea can compound dehydration, and dehydration worsens nausea. Cold or room-temperature drinks are often better tolerated than hot ones. If you are on the path to managing Mounjaro sickness and dietary adjustments are not enough, speak to your prescriber before reaching for over-the-counter antiemetics, some interact with other medicines, and your clinical team can advise on what fits your overall picture. Our prescribers at nume review your case personally; if side effects are affecting your quality of life, that conversation happens through our aftercare channel, seven days a week. Information on the full side-effect profile is on our Mounjaro side effects page.
Most Mounjaro-related nausea is self-limiting and manageable at home. Some symptoms are not. In January 2026, the MHRA issued a Drug Safety Update noting that acute pancreatitis is a known (though infrequent) risk with GLP-1 medicines. The symptom to act on immediately is severe, persistent stomach pain that radiates toward the back, with or without vomiting. That combination is not ordinary nausea; it needs urgent assessment. Gallbladder problems can present similarly, and both are listed in the Mounjaro prescribing information. If vomiting is severe enough to prevent you keeping fluids down for more than 24 hours, contact your GP or call 111. Dehydration from prolonged vomiting can affect kidney function, which is a separate clinical concern. You can also report any suspected side effect through the MHRA Yellow Card scheme, that reporting is how safety signals get spotted and acted on. For a deeper look at the pancreatitis risk specifically, our page on the incidence of pancreatitis with Mounjaro covers the current evidence in full. If you are thinking about starting treatment and want to understand the full picture before committing, checking your eligibility is a free, no-obligation first step with our clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.